Expressions and clinical significance of EGFR and EGFRv III in mammary tumor

YinNong Zhao,Ni He,Chao Ou,Ji Cao,Jun Chen,Jianyong Liu,WeiPing Yuan

2007-01-01

Abstract:To explore the expressions and clinical significance of EGFR and EGFRv III in human breast cancer tissues and benign mammary hyperplasia. Methodes: Supervision™ immunohistochemical staining (IHC) was used to detect the expressions of EGFR and EGFRv III in 30 specimens of human benign mammary hyperplasia tissues, 55 specimens of human breast cancer tissues, all their adjacent non-cancerous mammary tissues and metastasis lymph nodes. Results: The positive rate of EGFR in breast cancer tissues was significantly higher than that in adjacent non-cancerous mammary tissues and metastasis lymph node tissues (72.7%, 29.1% vs 58.3%, χ 2 = 5.326, P=0.021). The positive rate of EGFRv III in breast cancer tissues was significantly higher than that in adjacent non-cancerous mammary tissues and metastasis lymph node tissues (52.7%, 1.8% vs 45.8%, χ2=4.718, P=0.030). The positive rate of EGFR was significantly correlated with the pathologic grade (χ 2 = 11.840, P = 0.002), the number of local metastasis LN (χ2=13.715, P=0.000), ER-(χ2=10.785, P=0.007) and PR-(χ2=4.727, P=0.031). The positive rate of EGFRv III was significantly correlated with the pathologic grade (χ 2=5.280, P=0.024), distant metastasis (χ 2=5.612, P=0.019), the number of local metastasis LN (χ2 = 4.464, P = 0.038), ER-(χ2=3.960, P=0.049), PR-(χ2=17.517, P=0.000) and c-erbB-2 + (χ 2 = 7.424, P=0.005). Conclusion: Over-expressed EGFR and EGFRv III may be really related to initiation and progression of breast cancer. EGFRv III could be considered as the marker for predicting the initiation and prognosis of human breast cancer.